Skip to main content

Day: June 8, 2021

Mikael Fryklund appointed Interim CEO of Enedo Plc from June 8, 2021

Enedo Plc         Stock Exchange Release         8 June 2021 at 8:30 Mikael Fryklund appointed Interim CEO of Enedo Plc from June 8, 2021 The Board of Directors of Enedo Plc has appointed Mikael Fryklund Interim CEO of EnedoPlc. This appointment follows Vesa Leino´s decision to leave the company. Vesa will remainto introduce Mikael to the customers and to the company. Mikael Fryklund has been CEO of Hexpol AB (Publ, Large Cap) from 2017 to 2020, andbefore that President of Trelleborg Industrial Solutions and member of Group ManagementTrelleborg AB (Publ, Large Cap) from 2012 to 2017. Mikael has experience from othermanagement positions within the Trelleborg Group since 2002, and the Bosch Group. Mikaelholds a M.Sc. in Engineering and a B.Sc. in Business Administration, and he is born in 1963. “With the recruitment of Mikael Fryklund, Enedo...

Continue reading

NORBIT enters Nordic Semiconductor IoT partner program

Trondheim, 8 June 2021: NORBIT today announces signing of Partner Program Agreement with Nordic Semiconductor, a Norwegian fabless semiconductor company specializing in wireless communication technology, to explore joint opportunities stemming from Internet of Things (IoT). “With this agreement we have a strong partner to refer existing and potential customers who are looking for help to realize IoT products and solutions. NORBIT has in-house multidisciplinary R&D and world-class manufacturing and extensive experience working with wireless technology, customized integrated antennas, embedded software and lower power devices,” says Magnus Pedersen, Director of Sales in EMEA for Nordic Semiconductor. “Formalizing a partner program agreement with Nordic Semiconductor is a brick when building a new subsegment based on selected IoT/5G...

Continue reading

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 40% of the patient population responding suboptimally to anti-VEGF therapy Leuven, BE, Boston, MA, US – June 8, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, today announced the completion of patient enrollment into Part A of its two part Phase 2 study (“KALAHARI”) evaluating multiple injections of THR-149 for the treatment of DME. Dose selection data from Part A of the study is expected in the second half of 2021. THR-149, Oxurion’s most advanced drug candidate, is being developed to potentially become the treatment of choice for the up to 40% of DME patients, who respond suboptimally to anti-VEGF therapy. THR-149 acts through inhibition of the...

Continue reading

LHV Group results for May 2021

In May, LHV Group earned EUR 4.9 million in consolidated net profit. LHV Pank earned EUR 5 million and LHV Varahaldus EUR 0.4 million in net profit. The business volumes of the Estonian capital based financial group exhibited growth and the results surpass what was forecast in the financial plan. For the bank, May was primarily characterised by good results in terms of the growth of deposits and service fees, and in terms of client activity. The bank added nearly 3,900 clients. Among the increase in deposits, deposits of payment intermediaries, priced with a negative interest, also increased. The loan portfolio increased by EUR 35.4 million during the month. The quality of the loan portfolio remains good; discounts in the amount of EUR 0.6 million were made as a result of the growth of the portfolio. Among the more important events in...

Continue reading

Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home

The SARS-CoV-2 Antigen Self Test Nasal enables individuals to quickly and conveniently test themselves for COVID-19 at home using a simple nasal swab An early version of the test has already been available as a home-test in a number of European markets under local special approval pathways since February 2021 The test will be widely available to individuals through pharmacies and other locations in accordance to local guidelines and testing strategies The test works seamlessly with NAVIFY® Pass, Roche’s digital solution that allows individuals and healthcare providers to immediately store, display, and share their COVID-19 test results and vaccine status through a unique QR codeBasel, 08 June 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has received CE mark for its SARS-CoV-2 Antigen Self Test Nasal for at-home...

Continue reading

Hexagon Agility receives seventh set of orders for CNG/RNG trucks from major global logistics customer

Hexagon Agility, a business of Hexagon Composites, signed a master services agreement in June 2020 with a global logistics customer to deliver compressed natural gas (CNG) and renewable natural gas (RNG) fuel systems for medium and heavy-duty trucks. Hexagon Agility received its seventh set of orders in 2021 under this agreement, which represent an estimated value of USD 8 million (approx. NOK 66 million). Collectively, the orders placed in 2021 represent an estimated total value of USD 68 million (approx. NOK 562 million). “To achieve a meaningful and immediate impact on climate change, we need cleaner trucks and buses on our roadways now,” said Seung Baik, President, Hexagon Agility. “NGVA recently reported that, in 2020, 92% of all on-road fuel used in natural gas vehicles in California was renewable natural gas (RNG). And for the...

Continue reading

Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy

ORION CORPORATION                 PRESS RELEASE                8 JUNE 2021         AT 8.00 a.m. EEST Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy Orion Corporation and the Finnish Red Cross Blood Service have concluded an agreement on research collaboration with the aim of developing chimeric antigen receptor (CAR) T-cell therapy. Cancer immunotherapies, with CAR T-cell therapy as one form of therapy, have introduced entirely new possibilities for cancer treatment. In CAR T-cell therapy, the patient’s own white blood cells are genetically modified to attack the cancer and kill it. CAR T-cells are currently used to treat certain haematological cancers. The first T-cell therapies received marketing authorisation in the USA in 2017 and in Finland in 2019 for the treatment of recurrent acute...

Continue reading

Gold’n Futures Identifies Initial Area of Priority Gold Targets at the Hercules Project in Northern Ontario

Picture OneTable OneFigure OneCompilation Map with First Vertical Derivative Magnetic anomaly base map, showing past drilling, gold vein systems, target zones and area.VANCOUVER, British Columbia, June 08, 2021 (GLOBE NEWSWIRE) — Gold’n Futures Mineral Corp. (CSE: FUTR) (FSE: G6M), (OTC: GFTRF) (the “Company” or “Gold’n Futures”) is pleased to report that the compilation of historical data on the Hercules Gold Property has identified a large area encompassing several gold targets for exploration and resources expansion (“Area A”). Area A measures approximately 2,100 metres (“m”) long by 800m wide (Area A is depicted below in Figure One). Several partially delineated vein occurrences are contained within Area A that require further mapping, sampling and diamond drilling. In addition, a significant...

Continue reading

ST. JAMES GOLD CORP. (TSX-V: LORD) AMENDS OPTION AGREEEMNT

Vancouver, British Columbia, June 07, 2021 (GLOBE NEWSWIRE) — St. James Gold Corp. (the “Company”) (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) is pleased to announce that it has entered into agreements with Florin Resources Inc. (“Florin”) to amend the terms of the option and joint venture agreement (the “Option Agreement”) to acquire an interest in the Florin Gold Project covering 22,000 contiguous acres in the historic Tintina Gold Belt in the Yukon Territory, Canada (the “Florin Gold Project”), previously announced by the Company on April 6, 2021. The Option Agreement remains subject to the final approval of the TSX Venture Exchange (the “TSXV”). Material amendments made to the Option Agreement include the following:the Company’s first option, exercisable upon aggregate cash payments of $8,400,000 and aggregate share issuances...

Continue reading

SPK Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering

NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) — SPK Acquisition Corp. (NASDAQ: SPKAU, the “Company”) announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The units will be listed on The NASDAQ Capital Market (“NASDAQ”) and trade under the ticker symbol “SPKAU” beginning tomorrow, June 8, 2021. Each unit consists of one share of common stock and one right to receive one-tenth (1/10) of a share of common stock upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the common stock and rights will be listed on NASDAQ under the symbols “SPK” and “SPKAR,” respectively. The underwriters have been granted a 45-day option to purchase up to an additional 750,000 units offered...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.